Management is buying the same thing twice: proven demand from one place is being replicated into identified new places r
The model's full reasoning — Q1 2022 call → NOWe need answer YES or NO based on transcript. Need determine if management describes currently in middle of copying a part of its own business that already works into additional places where same demand already visible. Need identify specific proven instance, copies being stood up now, demand already identified at destination, replication large relative to company, results reflect original instance. Let's parse transcript. Company Establishment Labs, breast implants. They have Motiva implants in over 80 markets. They are seeking FDA approval for US. They have clinical trial. They have data. They are not yet in US. They have Flora tissue expander launched in Europe. They have Motiva Mia minimally invasive procedure, performing new cases, original 100-patient cohort. Regulatory clearance ongoing. They have China regulatory process, expectation to obtain regulatory approvals by end of year. They have new Sulayom Innovation Campus to produce more than half world's implants. They have Oaktree financing. Question asks: "does management describe the company as CURRENTLY IN THE MIDDLE OF COPYING A PART OF ITS OWN BUSINESS THAT IS ALREADY WORKING INTO ADDITIONAL PLACES WHERE THE SAME DEMAND IS ALREADY VISIBLE" — i.e., proven instance, standing up copies now, demand already identified at destination. Need see if any such situation. Possibly "Flora" tissue expander launched in Europe, expanding in 2 new markets this year. But is that copying a proven instance? They say "Adoption of Flora will take time but early efforts have been encouraging... Surgeons are adopting our technology with many making it their expander of choice. We continue to win tender contracts in Europe and are expanding in 2 new markets this year." That sounds like product launch in Europe, expanding to new markets. But is it "currently in middle of copying" a proven unit? Maybe not enough detail. Also "Motiva Mia" - they are performing new cases, tracking original 100-patient cohort, regulatory clearance ongoing, first cases in first half 2022. That's not proven yet? They have 100-patient cohort with 100% follow-up, outcomes support. But not yet commercially launched? They plan first cases in H1 2022. So not proven in real operation? They have original cohort but that's clinical, not commercial. Copies? No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| PUMP | ProPetro Holding Corp. | Q4 2023 | 2024-02-21 | C+ |
| BRBR | BellRing Brands, Inc. | Q4 2023 | 2023-11-21 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| VSEC | VSE Corporation | Q3 2022 | 2022-10-28 | B+ |
| FSLR | First Solar, Inc. | Q3 2022 | 2022-10-28 | C+ |
| CRL | Charles River Laboratories International | Q2 2022 | 2022-08-03 | C |
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| GDS | GDS Holdings Limited | Q2 2021 | 2021-08-17 | C+ |
| TPIC | TPI Composites, Inc. | Q3 2018 | 2018-11-11 | C |
| ALB | Albemarle Corporation | Q3 2018 | 2018-11-08 | B |
| IRT | Independence Realty Trust, Inc. | Q2 2018 | 2018-08-02 | B |
| FOLD | Amicus Therapeutics, Inc. | Q1 2018 | 2018-05-08 | C+ |
| AOSL | Alpha and Omega Semiconductor Limited | Q2 2018 | 2018-02-07 | B |
| VSAT | Viasat, Inc. | Q4 2017 | 2017-05-23 | C+ |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GDS · Q2 2021 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a clear, present-tense replication of their proven China-based data center platform into new markets (Hong Kong, Macau, Southeast Asia) where demand is already visible and committed. William Huang explicitly references the “proven” China edge-of-town model (land-and-expand MOUs, 500 000 sqm secured pipeline, hyperscale orders already landed) and states they are “currently developing two purpose-built data centers” in Hong Kong (HK1/HK2) with most capacity “already allocated to strategic customers pending contracts,” plus a new building (HK4) under agreement and a heads-of-agreement for HK3, creating “nearly 80 megawatts of purpose-built capacity through to 2027.” For Macau they have a JV to acquire brownfield sites for redevelopment (20 MW).
FOLD · Q1 2018 → YESThe question is about whether management describes the company as currently copying a proven part of its business into additional places where demand is already visible. YES The transcript shows management describing Galafold as a proven commercial offering (Q1 revenue $16.7M, 300% YoY growth, hundreds of patients, high compliance, 7 approvals, 18 countries with pricing/reimbursement) that is now being replicated into additional markets.
TPIC · Q3 2018 → YESThe question is whether management describes the company as currently in the middle of copying a part of its own business that is already working into additional places where the same demand is alread...YES The transcript shows management describing a proven manufacturing operation (existing dedicated lines and plants in the U.S.